Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

14.47
+0.65004.70%
Volume:411.24K
Turnover:5.90M
Market Cap:544.38M
PE:-8.41
High:14.60
Open:13.97
Low:13.74
Close:13.82
52wk High:17.79
52wk Low:8.60
Shares:37.62M
Float Shares:27.82M
Volume Ratio:1.31
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.27
PE(LYR):-6.67

Loading ...

Shares of Contineum Down 9.9% After J&J-Partnered Depression Drug Fails Mid-Stage Trial

THOMSON REUTERS
·
Yesterday

Contineum Therapeutics Price Target Cut to $24.00/Share from $26.00 by Jones Trading

Dow Jones
·
Sep 15

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Sep 15

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Sep 15

Contineum price target lowered to $19 from $20 at Baird

TIPRANKS
·
Sep 15

Contineum Therapeutics, Inc. : Leerink Partners Cuts Target Price to $22 from $25

THOMSON REUTERS
·
Sep 15

Stocks to Watch: Dave & Buster's, Contineum, Boxlight, Kestra Medical

Dow Jones
·
Sep 15

Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver

TIPRANKS
·
Sep 15

Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback

TIPRANKS
·
Sep 15

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live
·
Sep 15

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Dow Jones
·
Sep 15

Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results

TIPRANKS
·
Sep 15

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Reuters
·
Sep 15

Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint

TIPRANKS
·
Sep 15

Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint

TIPRANKS
·
Sep 15

Contineum Therapeutics, - Jnj-5120/Pipe-307 Well-Tolerated with no New Safety Signals

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics, - Analyses of Data Including Exploratory Endpoints are Ongoing

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics Reports Phase 2 Results for Jnj-5120/Pipe-307 for the Treatment of Major Depressive Disorder

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics, - Phase 2 Moonlight-1 Trial Did not Meet Primary Efficacy Endpoint

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Sep 15